# Vertex Pharmaceuticals Inc. MA

**VRTX**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000875320

**B**

**second fifth of 305 graded peers in healthcare**

rank 74 of 305; percentile 24.0; sampling error 2.8 points; lower is stronger

A B C D E


**B, the elk**



## Scoreboard


| | |
|---|---|
| **Profitability** | B/C<br>percentile 42.3 |
| **Solvency** | B<br>percentile 35.5 |
| **Growth and financing** | B/C<br>percentile 42.4 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $25.6B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: fortress balance sheet |
| **Inputs computable** | 10 of 13 |
| **Graded from** | filings received through Feb 13, 2026<br>279 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026 |
| **Last close** | $536.50<br>2026-11-18; market equity $136.0B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 13, 2026*

We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis ("CF"), sickle cell disease ("SCD"), transfusion dependent beta thalassemia ("TDT"), and acute pain, and we continue to serially innovate and advance next-generation clinical and research programs in these areas.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 42.3** | | | | | | |
| Gross profitability | 40.4% | 32.8% | | 32.8 | 346 | 2025-12-31 |
| Return on invested capital | not computable | 9.6% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | 1.3% | (6.7%) | | 83.6 | 756 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Gross margin stability, five years | 0.8 pts | 2.8 pts | 10.6 | 237 | 2025-12-31 |
| **Solvency, sleeve percentile 35.5** | | | | | |
| Altman Z double-prime | 7.50 | 0.31 | 13.1 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (3.61x) | | | |
| *latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 2.90x | 2.68x | 57.9 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 42.4** | | | | | |
| Revenue growth, three-year compound | 10.4% | 9.6% | 49.4 | 400 | 2025-12-31 |
| Free cash flow growth, three-year compound | (6.6%) | 11.1% | 80.6 | 94 | 2025-12-31 |
| Reinvestment rate | 43.2% | 33.9% | 45.0 | 101 | 2025-12-31 |
| Asset growth, three years | 12.2% | 3.2% | 28.5 | 663 | 2025-12-31 |
| Net share issuance, one year | (1.1%) | 1.6% | 8.7 | 625 | 2026-02-06 |

## Among 305 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 69 | Halozyme Therapeutics, Inc. (HALO) | 22.4 | A/B | |
| 70 | InnovAge Holding Corp. (INNV) | 22.7 | A/B | fortress balance sheet |
| 71 | Cronos Group Inc. (CRON) | 23.0 | B | |
| 72 | Warby Parker Inc. (WRBY) | 23.4 | B | |
| 73 | Guardant Health, Inc. (GH) | 23.7 | B | |
| 74 | Vertex Pharmaceuticals Inc. MA (VRTX) | 24.0 | B | |
| 75 | Pulmonx Corp. (LUNG) | 24.3 | B | fortress balance sheet |
| 76 | Rhythm Pharmaceuticals, Inc. (RYTM) | 24.7 | B | short runway |
| 77 | Axogen, Inc. (AXGN) | 25.0 | B | |
| 78 | NeuroPace Inc. (NPCE) | 25.3 | B | |
| 79 | GE HealthCare Technologies Inc. (GEHC) | 25.7 | B | |

## What the price implies

*at the 2026-11-18 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 22.8% | (1.7%) | 64 |
| Distance from 52-week high | (4.0%) | (30.2%) | 87 |
| EBIT to enterprise value | 3.2% | 0.5% | 64 |
| Free cash flow yield | 2.3% | 0.6% | 62 |
| Book value to price | 0.15 | 0.29 | 32 |
| Sales to price | 0.09 | 0.36 | 16 |
| Composite equity issuance, five years | (2.5%) | 13.5% | 29 |
| Relative strength against the sector, log excess return | 0.03 | (0.19) | 64 |
| Twelve-month failure probability, CHS model | 0.02% | 0.06% | 9 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | pass |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $5.0B |
| Operating cash flow, four quarters | $3.7B |
| Months of runway | not finite |
| Days since last periodic filing | 16 (10-Q received Nov 3, 2026) |
| Median daily dollar volume, 63 sessions | $591.0M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $12.0B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $1.7B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 3 | assets | us-gaap:Assets | $25.6B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 4 | net income | us-gaap:NetIncomeLoss | $4.0B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $3.6B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 6 | assets | us-gaap:Assets | $22.5B | 2024-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 7 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $11.0B | 2024-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 8 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $1.5B | 2024-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 9 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $9.9B | 2023-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 10 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $1.3B | 2023-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $8.9B | 2022-12-31 | 2025-02-13 | 10-K | 25-000053 |
| 12 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $1.1B | 2022-12-31 | 2025-02-13 | 10-K | 25-000053 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $7.6B | 2021-12-31 | 2024-02-15 | 10-K | 24-000062 |
| 14 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $904.2M | 2021-12-31 | 2024-02-15 | 10-K | 24-000062 |
| 15 | current assets | us-gaap:AssetsCurrent | $11.2B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $3.9B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $13.6B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | $4.2B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 19 | book equity | us-gaap:StockholdersEquity | $18.7B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 20 | liabilities | us-gaap:Liabilities | $7.0B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | $2.9B | 2020-12-31 | 2023-02-10 | 10-K | 23-000007 |
| 22 | interest expense | us-gaap:InterestExpense | $58.2M | 2020-12-31 | 2021-02-11 | 10-K | 21-000006 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $437.6M | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$492.6M | 2024-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $297.7M | 2024-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $3.5B | 2023-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $200.4M | 2023-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $4.1B | 2022-12-31 | 2025-02-13 | 10-K | 25-000053 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $204.7M | 2022-12-31 | 2025-02-13 | 10-K | 25-000053 |
| 30 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $209.8M | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 31 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $4.6B | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 32 | income tax | us-gaap:IncomeTaxExpenseBenefit | $690.0M | 2025-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 33 | current assets | us-gaap:AssetsCurrent | $9.6B | 2024-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $3.6B | 2024-12-31 | 2026-02-13 | 10-K | 26-000056 |
| 35 | assets | us-gaap:Assets | $22.7B | 2023-12-31 | 2025-02-13 | 10-K | 25-000053 |
| 36 | assets | us-gaap:Assets | $18.2B | 2022-12-31 | 2024-02-15 | 10-K | 24-000062 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 254,034,190 | 2026-02-06 | 2026-02-13 | 10-K | 26-000056 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 256,789,869 | 2025-02-07 | 2025-02-13 | 10-K | 25-000053 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.